<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82625">
  <stage>Registered</stage>
  <submitdate>22/02/2008</submitdate>
  <approvaldate>10/03/2008</approvaldate>
  <actrnumber>ACTRN12608000127303</actrnumber>
  <trial_identification>
    <studytitle>Treatment of chronically inflamed knee joints with aspiration and corticosteroid injection</studytitle>
    <scientifictitle>The effects of knee joint aspiration and corticosteroid injection on quadriceps muscle performance, flexion reflex excitability and lower limb function in patients with chronic arthritis.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Inflammatory arthritis of the knee joint</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Rheumatoid arthritis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Aspiration and a single dose intra-articular injection of 40mg Depomedrol. Participants will be followed up for 2 weeks after corticosteroid injection.</interventions>
    <comparator>None</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Quadriceps muscle function - peak isometric torque, electromyography (EMG) amplitude and muscle fibre conduction velocity</outcome>
      <timepoint>Baseline, post aspiration, 4 days post intervention, 2 weeks post intervention</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Lower limb function - self report questionnaires, 10 metre walk test, 6 minute walk test.</outcome>
      <timepoint>Baseline, 4 days post intervention, 2 weeks post intervention</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Flexion reflex excitability - threshold, Area under the curve at 1.2 x threshold</outcome>
      <timepoint>Baseline, post aspiration, 4 days post intervention, 2 weeks post intervention</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Pain - Visual analogue scale (VAS)</outcome>
      <timepoint>Baseline, 4 days post intervention, 2 weeks post intervention</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. A primary diagnosis of inflammatory arthritis, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, crystal arthritis. 
2. A clinically detectable knee joint effusion as well as other clinical signs and symptoms of knee joint synovitis including pain on motion, heat and tenderness on palpation.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1.Recent history of an intra-articular corticosteroid injection to the knee joint.
2.Any medical condition that may preclude the performance of maximum effort strength tests.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/06/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>AUT University</primarysponsorname>
    <primarysponsoraddress>55 Wellesly Street East
Auckland</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>AUT University</fundingname>
      <fundingaddress>55 Wellesly Street East
Auckland</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Health Research Council</fundingname>
      <fundingaddress>110 Stanley Street
Auckland</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Accident Compensation Corporation</fundingname>
      <fundingaddress>81-83 Molesworth Street
Wellington</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Government body</sponsortype>
      <sponsorname>Accident Compensation Corporation</sponsorname>
      <sponsoraddress>81-83 Molesworth Street
Wellington</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Government body</sponsortype>
      <sponsorname>Health Research Council</sponsorname>
      <sponsoraddress>110 Stanley Street
Auckland</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>University</othercollaboratortype>
      <othercollaboratorname>University of Auckland</othercollaboratorname>
      <othercollaboratoraddress>Park Road
Grafton
Auckland</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Joint disease often leads to an ongoing, reflex weakness of muscles acting across the damaged joint. This process is thought to occur at a spinal cord level and is called Arthrogenic Muscle Inhibition (AMI). At the knee joint, the quadriceps (the muscles at the front of the thigh) are preferentially affected by AMI. The quadriceps have an important protective function to the knee joint. Weakness and dysfunction due to AMI may reduce the shock attenuating ability of the muscles, increasing the forces acting at the knee and predisposing chronic arthritic joints to further injury or damage. While a number of studies have investigated the effects of swelling and joint disease on quadriceps function, few have looked at ways to overcome this problem. The purpose of this study is to measure changes in quadriceps muscle function, spinal reflex excitability and patients ability to perform day-to-day tasks after 1.) withdrawing fluid from their knee joints and then 2.) injecting a corticosteroid (an anti-inflammatory drug) into their joint. Results from the current study will provide important information concerning the mechanisms behind AMI and the rehabilitation of patients with chronic arthritic disease of the knee joint.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Northern Regional Ethics Committee</ethicname>
      <ethicaddress>Auckland</ethicaddress>
      <ethicapprovaldate>12/08/2007</ethicapprovaldate>
      <hrec>NTX/06/08/089</hrec>
      <ethicsubmitdate>4/08/2007</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>David Rice</name>
      <address>Health and Rehabilitation Research Centre
AUT University
Private Bag 92006
Auckland</address>
      <phone>+64 99219999 ext. 7032</phone>
      <fax />
      <email>david.rice@aut.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Jane Galle</name>
      <address>Health and Rehabilitation Research Centre
AUT University
Private Bag 92006
Auckland</address>
      <phone>+64 99219999 ext. 7194</phone>
      <fax />
      <email>jane.galle@aut.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>David Rice</name>
      <address>Health and Rehabilitation Research Centre
AUT University
Private Bag 92006
Auckland</address>
      <phone>+64 99219999 ext. 7032</phone>
      <fax />
      <email>david.rice@aut.ac.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>